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Thirty depressed in- and outpatients received serial dexamethasone sup- 
pression tests (DSTs). Plasma dexamethasone and cortisol concentrations 
were drawn at 1600 on the day following a I-mg oral dose of dexamethasone. 
The first DST was performed after patients were drug-free for a period of 
1 week; the second, third, and fourth DSTs while patients received anti- 
depressant medication. Dexamethasone and cortisol concentrations 
drawn in the drug-free period correlated significantly. The cortisol to 
dexamethasone ratio changed significantly with time in DST nonsuppressors, 
suggesting that nonsuppression is associated with an altered pharmacody- 
namic response of the hypothalamopituitary-adrenal axis to dexamethasone 
during depression. When dexamethasone concentrations from the drug-free 
period were compared with those drawn during antidepressant treatment, 
I no significant differences were noted. 
Pharmacokinetic factors may be important in inter- 
preting the dexamethasone suppression test (DST). 
Several studies have found an inverse relationship 
between the plasma dexamethasone and cortisol 
concentrations following dexamethasone. In most 
studies a DST nonsuppressor is designated by a 
cortisol plasma concentration of > 5  1 pg% at 
approximately 1600 on the day following dexametha- 
sone administration. It is likely that the plasma con- 
centration of dexamethasone resulting from a 1-mg 
oral dose might influence DST results to some 
degree. Arana et al. (1) noted that DST dexametha- 
sone plasma concentrations were lower in the non- 
suppressors compared with the suppressors in his 
population. Wiedemann 8z Holsboer (2) analyzed 
dexamethasone pharmacokinetics following a 1-mg 
oral dexamethasone dose &d found that the 
dexamethasone plasma concentrations were lower in 
nonsuppressors. Several other groups have also 
found a significant negative correlation between the 
dexamethasone and cortisol plasma concentrations 
following dexamethasone, although this factor alone 
has not accounted for DST nonsuppression in de- 
pressed persons (3-5). 
An interaction between dexamethasone and com- 
monly used medicine could result in erroneous 
DST results. Reports describing drug interactions 
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between dexamethasone and phenobarbital, phe- 
nytoin, estrogens or magnesium trisilicate have 
appeared in the literature (6-9). Two groups of 
investigators have reported that antidepressants do 
not affect DST results (10, 11). Although Hunt et al. 
(10) found that concomitant psychotropic medi- 
cation did not effect dexamethasone concentrations, 
they did not restudy the same patients at a later time 
point. Poland et al. (1 1) studied the same patients at 
3 time points and reported that there were no signifi- 
cant differences in dexamethasone concentrations 
before, during, or after antidepressant treatment. 
Carson et al. (12) examined the ratio of DST 
cortisol to dexamethasone plasma concentration. 
This ratio adjusts the cortisol concentration using 
the dexamethasone concentration. They found that 
the cortisol to dexamethasone ratios were signifi- 
cantly higher in DST nonsuppressors than in both 
normal controls and depressed patients who were 
suppressors. A longitudinal study of this relationship 
would reveal whether the relationship between 
dexamethasone and cortisol changes as the DST 
cortisol concentrations normalizes during antide- 
pressant treatment. 
To more fully explore some of these issues, in- and 
outpatients underwent serial DSTs, both when drug- 
free for at least one week and during treatment with 
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commonly used antidepressant drugs. We have 
addressed several questions in our group of patients: 
Is the dexamethasone concentration negatively 
correlated with the cortisol concentration following 
a dexamethasone dose in our population? Is there a 
significant change in dexamethasone concentrations 
when values obtained during antidepressant treat- 
ment are compared with values obtained in the same 
patients before they received antidepressants? Do 
D ST dexamethasone concentrations show signifi- 
cant variation if they are measured at different time 
points during a course of antidepressant medi- 
cation? Does the cortisol to dexamethasone ratio 
change longitudinally as DST nonsuppressors con- 
vert to suppressors? 
Materials and methods 
We retrospectively evaluated 30 inpatients (n = 15) 
and outpatients (n  = 15) from the depression pro- 
gram of the Department of Psychiatry at the Univer- 
sity of Michigan Medical Center. Serial DSTs were 
performed in these patients between September 1984 
and March 1987. All patients underwent one DST 
after being drug-free for at least 1 week, and three 
subsequent D STs while receiving the same antide- 
pressant medication. The dosage of antidepressant 
remained unchanged for at least 7 d prior to each 
DST completed during treatment. 
Patients receiving medication other than antide- 
pressants were included in the analyses if these drugs 
had never been reported to alter hepatic drug meta- 
bolism. Drug-free DSTs were performed on in- 
patients during the index admission and most of the 
subsequent DSTs were performed on an outpatient 
basis. All DSTs in the outpatients were performed 
on an outpatient basis. Patients were receiving anti- 
depressant medication when the second, third and 
fourth DSTs were performed. The time period 
between the drug-free DST and the second DST was 
6.3 k 3.8 weeks; the third DST followed the second 
by 2.0 k 1.7 weeks, and the fourth DST followed the 
third by 2.5 2.0 weeks. 
All patients met the Research Diagnostic Criteria 
for major depressive disorder. The mean Hamilton 
Rating Scale for Depression score during the pre- 
treatment period was 18.6 2 9.1, the mean age of the 
patients was 42.2 15.1 years (mean SD), and 
the male-female ratio was 12/18. The medicines 
included in the analysis were desipramine (n = lo), 
imipramine (n  = lo), phenelzine (n = 3), tranylcy- 
promine (n = 3), lithium ( n  = 7) and nortriptyline 
(n = 4). Some patients received combinations of 
these agents. Eight patients received nonpsychiatric 
medicines or benzodiazepines but none received 
neuroleptic s. 
The DST followed the procedure described by 
Carroll et al. (13) using 1 mg of dexamethasone. 
Both dexamethasone and cortisol plasma concentra- 
tions were drawn at 1600 on the following day and 
the result was considered nonsuppressive or abnor- 
mal if the 1600 post-dexamethasone plasma cortisol 
value exceeded 5 pg% . All samples were assayed by 
the same laboratory. Plasma cortisol was measured 
by the competitive protein binding technique of Pegg 
& Keane (14) as modified by De la Pena & 
Goldzieher (1 5) .  Plasma dexamethasone concentra- 
tions were measured by radioimmunoassay (16) 
using 3H-dexamethasone as a tracer, and dextran- 
coated charcoal to separate bound and free ligands. 
The antibody was obtained from rabbit antiserum 
raised against a bovine serum albumin conjugate of 
dexamethasone-3-carboxymeth yloxime-hemisuccin- 
ate, and was very specific for dexamethasone. Endo- 
genous steroids cross-reacted < 1 % and cortisol 
cross-reaction was not detectable until concentra- 
tions were > 16 pg/dl(O.5% cross-reactivity). Assay 
sensitivity was 10 pg/tube or 100 pg/ml using 100 pl 
of sample, and linear in the range from 0 to 
1500 ng/dl. The interassay coefficients of variation 
were 6.5% and 5.0% and the intra-assay coefficients 
of variation were 5.5% and 4.8% at mean dexame- 
thasone values of 109 ng/dl and 380 ng/dl, respec- 
tively. Assay recovery was 93 k 5 % in the range 0 to 
1500 ng/dl. 
Neither dexamethasone nor cortisol plasma con- 
centrations conformed to a normal distribution ; con- 
sequently, log-transformed values were used in the 
statistical analyses. The pre-treatment D ST dexame- 
thasone and cortisol plasma concentrations were 
examined using correlational analysis. The cortisol 
and dexamethasone plasma concentrations obtained 
during the serial DSTs were analyzed using one- or 
two-way ANOVA for repeated measures and 
unpaired Student’s t-test with Bonferroni adjust- 
ment of multiple tests. These statistics were per- 
formed using the StatView statistical software 
package (17). 
Results 
The dexamethasone and cortisol plasma concentra- 
tions at the drug-free time point are displayed in 
Fig. 1. At this time post-DST cortisol and dexame- 
thasone plasma concentrations were correlated 
(Y = - 0.49, P < .01, n = 30). However, no signifi- 
cant correlation was found between age and post- 
DST cortisol or dexamethasone plasma concentra- 
tions. 
In the total group of patients the mean 1600 DST 
dexamethasone concentrations were lowest during 
the drug-free period but there was no statistically 
significant time effect when the plasma dexametha- 
sone concentrations were analyzed using the one- 
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way ANOVA for repeated measures (Table 1). 
Dexamethasone concentrations in the patients 
who received imipramine (n = lo), desipramine 
(n  = lo), or the other antidepressants (n  = 10) were 
also compared using two-way ANOVA for repeated 
measures. This analysis revealed no group, or time 
effects and no group x time interaction (Table 1). 
During the drug-free period 7 of the 30 patients 
(23 2) were nonsuppressors. DST dexamethasone 
concentrations obtained at 1600 in suppressors and 
nonsuppressors were compared at all time points 
using a two-way ANOVA for repeated measures. 
There was no significant group x time interaction, 
nor were there any significant time or overall group 
effects (Fig. 2). Although the overall group effect did 
not reach statistical significance there was a trend 
Table 1. Plasma dexamethasone concentrations (ng/100 ml) in patients before and 
during treatment with desipramine, imipramine, or other antidepressants (mean f SD) 
DST Total 




Second 123.0 f 97.0 
Third 128.1 f90.3 
Fourth 120.6 f 9 1.8 
105.5t.93.9 67.1 f 62.5 111.3f 85.7 
96.5 f 74.1 129.6 f 122.5 142.9 f 92.6 
127.1 f91.6 125.2f 84.8 131.9f 103.3 
110.8 f 97.9 131.7 f 107.4 119.1 f 76.2 





NS for time and group effects, two-way ANOVA for 
repeated measures 
Dexamethasone Plasma Concentrations in 
Suppressors and Nonsuppressors (mean + sem) 
2oo I 
n = 7  
suppressors 
nonsuppressors 
n = 2 3  
o !  I I I I . 
drug-free 1 2 3 
time point 
Fig. 2. Dexamethasone plasma concentrations (ng/100 ml) at 1600 in patients who were suppressors (n = 23) or nonsuppressors 
( n  = 7) during the drug-free period, and subsequent time points. 
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towards lower dexamethasone concentrations in the 
nonsuppressors ( F  = 3.82, P = 0.06). Individual 
unpaired t-tests performed at the separate time 
points revealed significantly lower dexamethasone 
concentrations in the nonsuppressors during the 
drug-free period (P = 0.01) and at the first time point 
during antidepressant treatment (P < 0.05), 
although this last difference was not significant when 
subjected to the Bonferroni adjustment. 
The 1600 DST cortisol concentrations were ana- 
lyzed using a two-way ANOVA for repeated mea- 
sures. Since the group x time interaction was signifi- 
cant ( F  = 12.68, P < 0.001) the overall tests for 
group and time effects are invalid. Individual un- 
paired t-tests for groups were performed at each time 
point, and a significant difference, using the 
Bonferroni adjustment, was noted between the 
groups at the first time point (P < 0.001). These sig- 
nificant statistical findings are explained by the 
following; nonsuppressors exhibited higher cortisol 
concentrations than suppressors during the pre- 
treatment time point, and most of the nonsuppres- 
sors became suppressors during antidepressant 
treatment. 
The ratio of cortisol to dexamethasone was com- 
pared between the suppressors at all time points 
(n = 20) and the nonsuppressors who suppressed 
during all 3 DSTs performed during antidepressant 
treatment (n = 4), using a two-way ANOVA for re- 
peated measures (Fig. 3). The group x time inter- 
action (n = 24, F = 7.73, P < 0.001) was significant, 
thus invalidating the overall test for group and time 
effects. This interaction shows that a significant de- 
crease in the cortisol to dexamethasone ratio 
occurred in the nonsuppressors as they converted to 
suppressors. Individual t-tests performed for each 
time point revealed a significant difference, when 
= suppressors n = 2 0  - nonsuppresssors n = 4 
I 
I I I .1 
subjected to the Bonferroni adjustment, between the 
groups at the first time point P < 0.001). 
Discussion 
Arana et al. (1) and Carson et al. (12) found negative 
correlations between 1600 DST dexamethasone and 
cortisol plasma concentrations. Carr et al. (4) found 
a significant inverse curvilinear relationship between 
D ST dexamethasone and cortisol plasma concentra- 
tions. Since the dexamethasone concentration alone 
explained only a small amount of the variance of the 
cortisol concentrations, these authors concluded 
that an abnormal DST result is also a function of 
hypothalamopituitary-adrenal (HPA) axis dysregu- 
lation in MDD patients who are nonsuppressors. 
We also found that pre-treatment 1600 DST 
dexamethasone correlated negatively with cortisol 
plasma concentrations, explaining about 15 % of the 
variance of cortisol concentrations. 
Poland et al. (1 1) studied 10 endogenous depres- 
sives and found no significant differences in the 
0700, 1500 or 2300 post-DST dexamethasone plas- 
ma concentrations when he compared values ob- 
tained prior to, during, and after, treatment with 
antidepressants (primarily imipramine). However, 
this group examined only one time point during anti- 
depressant treatment and could not determine 
whether dexamethasone concentrations might be 
altered by the duration of antidepressant therapy. 
We have performed 3 serial DSTs during antidepres- 
sant therapy and have found no evidence that the 
duration of antidepressant therapy alters post-DST 
dexamethasone plasma concentrations. 
Our finding that antidepressant drugs in general, 
and desipramine and imipramine specifically, do not 
significantly alter the 1600 DST dexamethasone 
Cortisol to Dexamethasone Ratio in DST 
Suppressors and Nonsuppressors 
mean f sem 
DRUGFREE 1 2 3 
time points 
Fig. 3. Cortisol to dexarnethasone ratios at 1600 in patients who were consistently suppressors at all time points (n = 20) or 
nonsuppressors during the drug-free period but suppressors at the 3 subsequent time points during antidepressant therapy (n = 4). 
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Post-DST dexamethasone plasma concentrations 
concentrations during serial DSTs confirms and 
expands the results previously reported by Poland 
et al. (1 1). 
Although it was not statistically significant when 
analyzed using the ANOVA with repeated measures, 
the nonsuppressors in our group exhibited lower 
1600 dexamethasone concentrations than the 
suppressors, both during the drug-free period and 
when they received antidepressants. The lack of a 
statistically significant difference may be due to the 
small sample population, since t-tests showed signifi- 
cant differences at 2 of the time points and a signifi- 
cant group effect was found when one patient with 
a marginally high cortisol (4.53 pg%) was included 
in the nonsuppressor group. Wiedemann & 
Holsboer (2) found that nonsuppressors exhibited 
significantly lower dexamethasone plasma concen- 
trations at most time points compared with suppres- 
sors following a single oral dose of dexamethasone. 
However, they did not study their patients longi- 
tudinally to determine whether dexamethasone con- 
centrations changed when nonsuppressors con- 
verted to suppressors during treatment. Poland et al. 
(1 1) found no change in dexamethasone concentra- 
tions in either suppressors or nonsuppressors when 
he compared 1600 DST samples drawn prior to 
treatment, during treatment, and post-treatment in 
his depressed population. In our nonsuppressors the 
dexamethasone concentrations did not change signi- 
ficantly over time, regardless of their suppressor 
status. 
In the manner previously described by Carson 
et al. (12) we adjusted the cortisol concentration 
with the concentration of dexamethasone. As the 
cortisol concentrations normalized over time in our 
nonsuppressors, the cortisol to dexamethasone 
ratios in the nonsuppressors showed a significant 
decrease. The cortisol to dexamethasone ratios in 
nonsuppressors decreased to values similar to those 
observed in the DST suppressors and were not ac- 
companied by a significant change in dexametha- 
sone concentration. 
Conclusion 
In conclusion, we found the same inverse correlation 
between dexamethasone and cortisol concentrations 
that has been reported by other investigators. In 
agreement with these investigators, we do not believe 
that this relationship totally explains the pheno- 
menon of DST nonsuppression in depression. We 
also found that antidepressant drug therapy in 
general, and specifically in patients receiving imi- 
pramine or desipramine, did not statistically signifi- 
cantly change in the 1600 DST plasma dexametha- 
sone concentrations in our patient population. 
Further research would determine whether the de- 
pressed state is another important variable that 
affects dexamethasone plasma concentrations ; un- 
fortunately we were not able to evaluate this in our 
data set. 
The difference between the dexamethasone plas- 
ma concentrations in DST suppressors and non- 
suppressors was not statistically significant (perhaps 
because of the small number of nonsuppressors in 
our sample), but we found a definite trend towards 
lower dexamethasone plasma concentrations in non- 
suppressors. Although the dexamethasone concen- 
trations did not change significantly over time in 
either the suppressors or nonsuppressors, we found 
that the cortisol to dexamethasone ratio in DST 
nonsuppressors decreased significantly over time as 
nonsuppressors converted to suppressors. This 
finding strengthens the hypothesis that nonsup- 
pression is associated with an altered pharmacody- 
namic response of the HPA to dexamethasone 
during depression. 
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